natgillin/translations-raw huggingface dataset:
TEVA UK Ltd, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
TEVA UK Ltd, Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, Velika Britanija
Tevagrastim 30 MIU/0.5 mL
Tevagrastim 30 000 k.i.e./0,5 ml
Tevagrastim 30 MIU/0.5 mL
Tevagrastim 30 000 k.i.e./0.5 ml
Tevagrastim 30 MIU/0.5 mL solution for injection or infusion
Tevagrastim 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje
Tevagrastim 30 MIU/0.5 mL solution for injection or infusion Filgrastim
Tevagrastim 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje Filgrastim
Tevagrastim 30 MIU/0.5 mL solution for injection or infusion Tevagrastim 48 MIU/0.8 mL solution for injection or infusion
Tevagrastim 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje Tevagrastim 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje
Tevagrastim 48 MIU/0.8 mL
Tevagrastim 48 000 k.i.e./0,8 ml
Tevagrastim 48 MIU/0.8 mL solution for injection or infusion
Tevagrastim 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje
Tevagrastim 48 MIU/0.8 mL solution for injection or infusion Filgrastim
Tevagrastim 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje filgrastim
Tevagrastim 48 MIU/0.8 mL: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 mL solution.
Tevagrastim 48 000 k.i.e./0,8 ml: ena napolnjena injekcijska brizga vsebuje 48 milijonov mednarodnih enot [i.e.] (480 mikrogramov) zdravila filgrastim v 0,8 ml raztopine.
Tevagrastim and bone marrow transplantation
Zdravilo Tevagrastim in presaditev kostnega mozga
Tevagrastim and chemotherapy
Zdravilo Tevagrastim in kemoterapija
Tevagrastim and neutropenia in patients with HIV infection
Zdravilo Tevagrastim in nevtropenija pri bolnikih, okuženih s HIV
Tevagrastim and peripheral blood stem cell mobilisation
Zdravilo Tevagrastim in zbiranje matičnih celic iz periferne krvi
Tevagrastim and severe chronic neutropenia
Zdravilo Tevagrastim in huda kronična nevtropenija
Tevagrastim contains sorbitol and sodium
Zdravilo Tevagrastim vsebuje sorbitol in natrij
Tevagrastim contains sorbitol.
Zdravilo Tevagrastim vsebuje sorbitol.
Tevagrastim contains the active substance filgrastim.
Tevagrastim vsebuje zdravilno učinkovino filgrastim.
Tevagrastim has not been tested in pregnant women.
Zdravila Tevagrastim pri nosečnicah niso preizkusili.
Tevagrastim is a solution for injection or infusion in a pre-filled syringe.
Zdravilo Tevagrastim je raztopina za injiciranje ali infundiranje v napolnjeni injekcijski brizgi.
Tevagrastim is a ‘biosimilar’ medicine.
Zdravilo Tevagrastim je podobno biološko zdravilo.
Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
Zdravilo Tevagrastim se uporablja za zbiranje perifernih krvotvornih matičnih celic (PBPC).
Tevagrastim is supplied in packs of 1, 5 or 10 pre-filled syringes or multipacks of 10 (2 packs of 5) pre-filled syringes with injection needle and with or without a needle safety guard.
Zdravilo Tevagrastim je mogoče dobiti v pakiranjih po 1, 5 ali 10 napolnjenih injekcijskih brizg ali v obliki skupnih pakiranj po 10 (2 pakiranji po 5) napolnjenih injekcijskih brizg z injekcijsko iglo, z varnostno zaščito za iglo, ali brez nje.
Tevagrastim is useful in several different conditions, which are:
Zdravilo Tevagrastim pomaga pri več različnih stanjih, med katere spadajo:
Tevagrastim treatment will last for 4 to 5 days.
Zdravljenje z zdravilom Tevagrastim bo trajalo 4 do 5 dni.
Tevagrastim treatment will last for up to 2 weeks and in exceptional cases longer.
Zdravljenje z zdravilom Tevagrastim bo trajalo do dveh tednov, le v izjemnih primerih bo trajalo dlje.
TEXT FOR SYRINGE LABEL
BESEDILO NA NALEPKI BRIZGE
TEXT FOR SYRINGE LABEL – EU/1/99/126/001
BESEDILO NA NALEPKI NAPOLNJENE INJEKCIJSKE BRIZGE – EU/1/99/126/001
TEXT FOR SYRINGE LABEL – EU/1/99/126/003-005
BESEDILO NA NALEPKI NAPOLNJENE INJEKCIJSKE BRIZGE – EU/1/99/126/003-005
TEXT FOR SYRINGE LABEL – EU/1/99/126/022 (For paediatric use)
BESEDILO NA NALEPKI INJEKCIJSKE BRIZGE – EU/1/99/126/022 (za uporabo pri otrocih)
TEXT FOR THE BOTTLE LABEL AND THE OUTER CARTON
BESEDILO ZA NALEPKO NA PLASTENKI IN ZUNANJO OVOJNINO
Text for the immediate packaging of 15 ml and 20 ml vials
Besedilo za primarno ovojnino za 15-, in 20-mililitrske viale
Text for the immediate packaging of 15 ml, 20 ml and 30 ml pre-filled syringes
Besedilo za primarno ovojnino za 15-, 20- in 30-mililitrske napolnjene injekcijske brizge
Text for the immediate packaging of the 10 ml pre-filled syringe
Besedilo za stično ovojnino za 10-mililitrsko napolnjeno injekcijsko brizgo
Text for the immediate packaging of the 10 ml vial
Besedilo za stično ovojnino za 10-mililitrsko vialo
Text for the outer packaging of 10 ml, 15 ml and 20 ml vials
Besedilo za zunanjo ovojnino za 10-, 15- in 20-mililitrske viale
Text for the outer packaging of 10 ml, 15 ml, 20 ml and 30 ml pre-filled syringes
Besedilo za zunanjo ovojnino za 10-, 15-, 20- in 30-mililitrske napolnjene injekcijske brizge
Text for the protective bag
Besedilo na zaščitni vrečki
TEXT FOR TRAY BACK – EU/1/99/126/013-015 (25 mg Pre-filled Syringe)
BESEDILO NA PODSTAVKU - EU/1/99/126/013-015 (25 mg napolnjena injekcijska brizga)
TEXT FOR TRAY BACKING – EU/1/99/126/001
BESEDILO NA PODSTAVKU - EU/1/99/126/001
TEXT FOR TRAY BACKING – EU/1/99/126/002
BESEDILO NA PODSTAVKU - EU/1/99/126/002
TEXT FOR TRAY BACKING – EU/1/99/126/003-005
BESEDILO NA PODSTAVKU - EU/1/99/126/003-005
TEXT FOR TRAY BACKING – EU/1/99/126/006-008 (50 mg Vial only)
BESEDILO NA PODSTAVKU - EU/1/99/126/006-008 (samo za 50 mg vialo)
TEXT FOR TRAY BACKING – EU/1/99/126/009-011 (50 mg Convenience Pack)
BESEDILO NA PODSTAVKU - EU/1/99/126/009-011 (50 mg bolniku prijazno pakiranje)
TEXT FOR TRAY BACKING – EU/1/99/126/016-018 (50 mg Pre-filled Syringe)
BESEDILO NA PODSTAVKU - EU/1/99/126/016-018 (50 mg napolnjena injekcijska brizga)
TEXT FOR TRAY BACKING – EU/1/99/126/019-021 (50 mg Pre-filled Pen)
BESEDILO NA PODSTAVKU - EU/1/99/126/019-021 (50 mg napolnjeni injekcijski peresnik)
TEXT FOR TRAY BACKING – EU/1/99/126/022 (For paediatric use)
BESEDILO NA PODSTAVKU - EU/1/99/126/022 (za uporabo pri otrocih)
TEXT FOR VIAL LABEL
BESEDILO NA NALEPKI VIALE
TEXT FOR VIAL LABEL – EU/1/99/126/001
BESEDILO NA NALEPKI VIALE – EU/1/99/126/001
TEXT FOR VIAL LABEL – EU/1/99/126/002
BESEDILO NA NALEPKI VIALE – EU/1/99/126/002
TEXT FOR VIAL LABEL – EU/1/99/126/003-005
BESEDILO NA NALEPKI VIALE – EU/1/99/126/003-005
TEXT FOR VIAL LABEL – EU/1/99/126/006-008 (50 mg Vial only)
BESEDILO NA NALEPKI VIALE – EU/1/99/126/006-008 (samo za 50 mg vialo)
TEXT FOR VIAL LABEL – EU/1/99/126/009-011 (50 mg Convenience Pack)
BESEDILO NA NALEPKI VIALE – EU/1/99/126/009-011 (50 mg bolniku prijazno pakiranje)
TEXT FOR VIAL LABEL – EU/1/99/126/022 (For paediatric use)
BESEDILO NA NALEPKI VIALE – EU/1/99/126/022 (za uporabo pri otrocih)
TEXT TO APPEAR ON THE ALUMINIUM FOIL WHICH IS USED FOR SEALING TRANSPARENT PLASTIC TRAY CONTAINING THE CARTRIDGE
Besedilo, natisnjeno na aluminijski foliji, ki se uporablja za zaprtje prosojnega plastičnega ležišča, v katerem je vložek
Teysuno + Cisplatin 75 mg/m2 (N=521)
Teysuno + cisplatin 75 mg/m2 (n = 521)
Teysuno 15 mg/4.35 mg/11.8 mg capsules tegafur/gimeracil/oteracil
Teysuno 15 mg/4,35 mg/11,8 mg kapsule tegafurum/gimeracilum/oteracilum
Teysuno 15 mg/4.35 mg/11.8 mg hard capsules
Teysuno 15 mg/4,35 mg/11,8 mg trde kapsule
Teysuno 20 mg/5.8 mg/15.8 mg capsules tegafur/gimeracil/oteracil
Teysuno 20 mg/5,8 mg/15,8 mg kapsule tegafurum/gimeracilum/oteracilum
Teysuno 20 mg/5.8 mg/15.8 mg hard capsules
Teysuno 20 mg/5,8 mg/15,8 mg trde kapsule
Teysuno belongs to the fluoropyrimidine class of medicine known as “antineoplastic agents” which stop the growth of cancer cells.
Zdravilo Teysuno sodi v skupino fluoropirimidinov, znanih kot "antineoplastična zdravila", ki zaustavijo rast rakavih celic.
Teysuno cannot be substituted for other oral fluoropyrimidine medicine.
Zdravila Teysuno ne smete uporabiti kot nadomestek za druga peroralna zdravila s fluoropirimidinom;
Teysuno capsules are taken with water at least one hour
Kapsule zdravila Teysuno se jemljejo z vodo vsaj eno uro pred obrokom ali po njem.
Teysuno contains
Zdravilo Teysuno vsebuje
Teysuno contains the active substances tegafur gimeracil and oteracil.
Zdravilo Teysuno vsebuje zdravilne učinkovine tegafur, gimeracil in oteracil.
Teysuno dose
Odmerek zdravila Teysuno
Teysuno dose calculations
Izračuni odmerkov zdravila Teysuno
Teysuno dose modification
Sprememba odmerka zdravila Teysuno
Teysuno has a moderate influence on the ability to drive and use machines as fatigue, dizziness, blurred vision, and nausea are common adverse reactions of Teysuno in combination with cisplatin.
Zdravilo Teysuno ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji, kajti pogosti neželeni učinki zdravila Teysuno v kombinaciji s cisplatinom so utrujenost, omotica, zamegljen vid in navzea.
Teysuno has moderate influence on the ability to drive and use machines as fatigue, dizziness, blurred vision, and nausea are common adverse reactions of Teysuno in combination with cisplatin.
Zdravilo Teysuno ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji, kajti pogosti neželeni učinki zdravila Teysuno v kombinaciji s cisplatinom so utrujenost, omotica, zamegljen vid in navzea.
Teysuno is not recommended for children under 18 years of age.
Zdravila Teysuno ne priporočajo za otroke, mlajše od 18 let.
Teysuno must not be used with sorivudine or brivudine or within 4 weeks of the last dose of sorivudine or brivudine.
Zdravila Teysuno se ne sme uporabljati skupaj s soruvidinom ali brivudinom oziroma znotraj štiritedenskega obdobja po zadnjem odmerku soruvidina ali brivudina.
Teysuno should be taken at least one hour before or one hour after a meal.
Zdravilo Teysuno se jemlje vsaj eno uro pred obrokom ali eno uro po obroku.
Teysuno with food and drink
Zdravilo Teysuno skupaj s hrano in pijačo
Teл.: + 359 2 9620948/ +359 2 9620931
Teл.: +359 2 9620948 / +359 2 9620931
Teл.: + 359 2 970 47 47
Teл: + 359 2 970 47 47
Teл.: +359 2 9321 861
Teл.: +359 2 9321 680
Teл.: +359-(0)2 962 30 49
Teл.: + 359-(0) 2 962 30 49
Teл.: +359-(0)2 962 30 49
Teл.: + 359-(0)2 962 30 49
TG (%)
Triglic eridi (%)
TG (%)
Trigliceridi (%)
Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys. any bisphosphonate medicine, since the combined effects of these medicines taken together with Zoledronic Acid Teva are unknown.
talidomid (zdravilo, ki ga uporabljamo pri zdravljenju določenih vrst krvnega raka, ki zajemajo kosti) ali druga zdravila, ki lahko škodujejo ledvicam, če se zdravite z zdravilom, ki vsebuje kateri koli drug difosfonat, saj skupni učinki jemanja teh zdravil skupaj z zdravilom Zoledronska kislina Teva niso znani.
thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys. other medicines that also contain zoledronic acid and are used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic acid medac are unknown. anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
talidomid (zdravilo, ki ga uporabljamo pri zdravljenju določenih vrst krvnega raka, ki vključujejo kosti) ali druga zdravila, ki lahko škodujejo ledvicam, druga zdravila, ki prav tako vsebuje zoledronsko kislino, in jih uporabljamo pri zdravljenju osteoporoze in drugih nerakavih bolezni kosti, ali katerega koli od drugih difosfonatov, saj učinki navedenih zdravil v kombinaciji z zdravilom Zoledronska kislina medac niso znani, antiangiogena zdravila (uporabljamo jih pri zdravljenju raka), ker kombinacijo le-teh z zdravilom Zoledronska kislina medac povezujejo s povečanim tveganjem za osteonekrozo čeljustnic.
thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys. other medicines that also contain zoledronic acid and are used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic acid medac are unknown. anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
talidomid (zdravilo, ki ga uporabljamo pri zdravljenju določenih vrst krvnega raka, ki zajemajo kosti) ali druga zdravila, ki lahko škodujejo ledvicam, druga zdravila, ki prav tako vsebuje zoledronsko kislino, in jih uporabljamo pri zdravljenju osteoporoze in drugih nerakavih bolezni kosti, ali katerega koli od drugih difosfonatov, saj učinki navedenih zdravil v kombinaciji z zdravilom Zoledronska kislina medac niso znani, antiangiogena zdravila (uporabljamo jih pri zdravljenju raka), ker kombinacijo le-teh z zdravilom Zoledronska kislina medac povezujejo s povečanim tveganjem za osteonekrozo čeljustnic.
Thalidomide Celgene 50 mg hard capsules
Thalidomide Celgene 50 mg trde kapsule
Thalidomide Celgene 50 mg hard capsules Thalidomide
Thalidomide Celgene 50 mg trde kapsule talidomid
Thalidomide Celgene are white hard capsules marked “Thalidomide Celgene 50 mg”.
Thalidomide Celgene so bele trde kapsule, označene s „Thalidomide Celgene 50 mg“.
Thalidomide Celgene can be taken with or without food (see section 3, “How to take Thalidomide Celgene”).
Zdravilo Thalidomide Celgene se lahko jemlje s hrano ali brez nje (glejte poglavje 3 „Kako jemati zdravilo Thalidomide Celgene“).
Thalidomide Celgene can be used for a maximum of 12 treatment cycles, with each cycle lasting six weeks.
Zdravilo Thalidomide Celgene se lahko uporablja največ 12 ciklov zdravljenja, pri čemer vsak cikel traja šest tednov.
Thalidomide Celgene has minor or moderate influence on the ability to drive and use machines.
Zdravilo Thalidomide Celgene ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Thalidomide Celgene in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.
Zdravilo Thalidomide Celgene v kombinaciji z melfalanom in prednizonom za primarno zdravljenje bolnikov z nezdravljenim diseminiranim plazmocitomom, starih ≥ 65 let ali za bolnike, pri katerih zdravljenje z visokimi odmerki kemoterapije ni primerno.
Thalidomide Celgene is a medicine containing the active substance thalidomide.
Thalidomide Celgene je zdravilo, ki vsebuje zdravilno učinkovino talidomid.
Thalidomide Celgene is not recommended for use in children and young people under 18 years.
Uporaba zdravila Thalidomide Celgene ni priporočljiva pri otrocih in mladostnikih, starih manj kot 18 let.
Thalidomide Celgene is used to treat multiple myeloma (a cancer of the bone marrow) in combination with the cancer medicines melphalan and prednisone in patients who have not been treated for multiple myeloma before.
Zdravilo Thalidomide Celgene se uporablja za zdravljenje multiplega mieloma (raka kostnega mozga) v kombinaciji z zdravili za zdravljenje raka melfalanom in prednizonom pri bolnikih s predhodno nezdravljenim multiplim mielomom.
Thalidomide Celgene is used with two other medicines called ‘melphalan’ and ‘prednisone’ to treat adults aged 65 years and over, with a type of cancer called multiple myeloma.
Zdravilo Thalidomide Celgene se uporablja z dvema drugima učinkovinama, imenovanima 'melfalan' in 'prednizon' za zdravljenje odraslih bolnikov, starih 65 let in več, za vrsto raka, imenovanega diseminirani plazmocitom.
Thalidomide Celgene should be taken as a single dose at bedtime, to reduce the impact of somnolence.
Zdravilo Thalidomide Celgene se jemlje v enkratnem odmerku pred spanjem, za zmanjšanje vpliva zaspanosti.
Thalidomide Celgene was studied in one main study involving 447 patients with multiple myeloma.
Zdravilo Thalidomide Celgene so proučevali v eni glavni študiji, ki je vključevala 447 bolnikov z multiplim mielomom.
Thalidomide Celgene with food, drink and alcohol
Zdravilo Thalidomide Celgene skupaj s hrano, pijačo in alkoholom
Thalidomide Celgene works by helping the body’s immune system and directly attacking the cancer.
Zdravilo Thalidomide Celgene deluje tako, da pomaga imunskemu sistemu telesa z neposrednim napadom na raka.
Thalidomide frequently causes somnolence.
Talidomid pogosto povzroči somnolenco.
Thalidomide has a chiral centre and is used clinically as a racemate of (+)-(R)- and (-)-(S)- thalidomide.
Talidomid ima kiralni center in se uporablja klinično kot racemat (+)-(R)- in (-)-(S)-talidomida.
Thalidomide has sedative properties thus may enhance the sedation induced by anxiolytics, hypnotics, antipsychotics, H1 anti-histamines, opiate derivatives, barbiturates and alcohol.
Talidomid ima sedativne lastnosti in lahko poveča sedacijo, ki jo povzročijo anksiolitiki, hipnotiki, antipsihotiki, antihistaminiki H1, derivati opiata, barbiturati in alkohol.
Thalidomide is a known human teratogen that causes severe life- threatening birth defects.
Talidomid je za človeka znana teratogena učinkovina, ki povzroča hude, smrtno nevarne okvare ploda.
Thalidomide is a known human teratogen that causes severe life- threatening birth defects.
Talidomid je za človeka znana teratogena zdravilna učinkovina, ki povzroča hude, smrtno nevarne okvare ploda.
Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.
Talidomid je za človeka znana teratogena zdravilna učinkovina, ki povzroča hude, smrtno nevarne okvare ploda.
Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.
Talidomid je za človeka znana teratogena zdravilna učinkovina, ki povzroča hude, smrtno nevarne, okvare ploda.
Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects.
Talidomid je znana za človeka teratogena zdravilna učinkovina, ki povzroča hude, smrtno nevarne okvare ploda.
Thalidomide is a powerful human teratogen, inducing a high frequency (about 30%) of severe and live-threatening birth defects such as: ectromelia (amelia, phocomelia, hemimelia) of the upper and/or lower extremities, microtia with abnormality of the external acoustic meatus (blind or absent), middle and internal ear lesions (less frequent), ocular lesions (anophthalmia, microphthalmia), congenital heart disease, renal abnormalities.
Talidomid je močan humani teratogen, ki inducira visoko pogostnost (okrog 30 %) resnih in smrtno nevarnih prirojenih okvar, kot so: ektromelija (amelija, fokomelija, hemimelija) zgornjih in/ali spodnjih okončin, mikrotija z okvarami zunanjega slušnega kanala (slep ali manjkajoč), lezije srednjega in notranjega ušesa (manj pogosto), lezije oči (anoftalmija, mikroftalmija), prirojena srčna bolezen, okvare ledvic.
Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life- threatening birth defects.
Talidomid je močan humani teratogen, ki inducira visoko pogostnost resnih in smrtno nevarnih prirojenih okvar.
Thalidomide is a powerful human ‘teratogen’, meaning that it has a harmful effect on the unborn child, causing severe and life-threatening birth defects.
Talidomid je močan humani teratogen, kar pomeni, da škodljivo učinkuje na nerojenega otroka ter povzroča resne in smrtno nevarne prirojene okvare.
Thalidomide is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see section 4.3)
Talidomid je kontraindiciran med nosečnostjo in pri ženskah v rodni dobi, razen če so izpolnjeni vsi pogoji programa Thalidomide Celgene za preprečevanje nosečnosti (glejte poglavje 4.3).
Thalidomide is present in the semen of male patients at levels similar to plasma concentrations.
Talidomid je prisoten v spermi moških bolnikov v podobnih koncentracijah kot v plazmi.
Thalidomide may also potentially aggravate existing neuropathy and should therefore not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks.
Talidomid lahko tudi poslabša obstoječo nevropatijo. zato ga bolniki s kliničnimi znaki ali simptomi za periferno nevropatijo ne smejo uporabljati, razen če so klinične koristi večje kot tveganja.
Thalidomide may cause fatigue, dizziness, somnolence and blurred vision (see section 4.8).
Talidomid lahko povzroči utrujenost, omotico, somnolenco in zamegljen vid (glejte poglavje 4.8).
Thalidomide must never be used by women who are pregnant or by women who could become pregnant unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met.
Nosečnice ali ženske, ki lahko zanosijo, ne smejo nikoli jemati talidomida, razen če so izpolnjeni vsi pogoji programa Thalidomide Celgene za preprečevanje nosečnosti.
Thalidomide passes into semen.
Talidomid prehaja v spermo.
Thalidomide should be discontinued if a skin rash occurs and only resumed following appropriate clinical evaluation.
Uporabo talidomida je treba ukiniti, če se pojavi kožni izpuščaj, in jo nadaljevati šele po ustrezni klinični oceni.
Thalidomide shows immunomodulatory anti-inflammatory and potential anti-neoplastic activities.
Talidomid kaže imunomodulatorne protivnetne in potencialno antineoplastične aktivnosti.
Thalidomide treatment must be initiated and monitored under the supervision of physicians with expertise in managing immunomodulatory or chemotherapeutic agents and a full understanding of the risks of thalidomide therapy and monitoring requirements (see section 4.4).
Zdravljenje z zdravilom Thalidomide Celgene lahko začne in nadzira samo zdravnik, ki ima strokovno znanje za ravnanje z imunomodulatorji ali kemoterapevtiki in popolnoma razume tveganja zdravljenja s talidomidom ter zahteve glede nadzorovanja.
Thalidomidea,b
talidomida,b
Thame, OX9 3EZ United Kingdom
Thame, OX9 3EZ Velika Britanija
Thame, Oxon, OX9 3EZ, United Kingdom
Thame, Oxon, OX9 3EZ, Velika Britanija
than 2 years)
od 2 let)
That activity should be taken into account in the evaluation of the overall coagulation status of the patient during the switch (see section 4.2).
Ta učinek je treba upoštevati pri oceni celotnega koagulacijskega statusa bolnika med prehodom (glejte poglavje 4.2).
That additional plasma caffeine monitoring and dosage adjustment may be necessary in at risk situations such as preterm infants:
Podatek, da bo morda potrebno dodatno spremljanje kofeina v plazmi in prilagajanje odmerka v tveganih situacijah, kot je to pri prezgodaj rojenih dojenčkih:
That all patients should be counselled about:
vsi bolniki morajo prejeti opozorilno kartico za bolnika in biti poučeni
That all patients should be provided with a Patient alert card and be counselled about:
da morajo vsi bolniki prejeti kartico z opozorili za bolnika in da jim moramo svetovati o:
That all patients should be provided with a Patient alert card and be counselled about:
Navodilo, da morajo vsi bolniki prejeti kontrolno kartico in da jih je treba poučiti o:
That all suspected adverse reactions should be reported in accordance with national reporting requirements
Da je treba o vseh primerih suma na neželene učinke poročati skladno z nacionalnimi zahtevami glede poročanja.
that are on the skin only; which have not responded to your HIV treatment;
ki se nahajajo le na koži, ki se niso odzvale na vaše HIV zdravljenje,
That baseline plasma levels may need measuring because of an increased risk of toxicity if
Podatek, da je treba osnovne ravni v plazmi morda izmeriti, ker obstaja povečano tveganje toksičnosti, če:
That blood glucose need to be closely monitored during the switch and the initial weeks thereafter;
Da si morajo med prehodom in v prvih tednih po njem skrbno kontrolirati glukozo v krvi.
That caffeine and theophylline should not be used concurrently
Podatek, da se kofeina in teofilina ne sme uporabljati sočasno.